| Dr Jeffrey H Bordelon, MD | |
|
1 Mercy Ln, Suite 201, Hot Springs, AR 71913-6442 | |
| (501) 609-2222 | |
| (501) 321-9689 |
| Full Name | Dr Jeffrey H Bordelon |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 1 Mercy Ln, Hot Springs, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033267679 | NPI | - | NPPES |
| 154970001 | Medicaid | AR | |
| 5N0126972 | Other | MEDICARE LINKED |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | E4139 (Arkansas) | Secondary |
| 207R00000X | Internal Medicine | E-4139 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Hospital | Pensacola, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pensacola Hospitalist Physicians Llc | 5395159818 | 52 |
News Archive
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute's long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group
Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Nearly 75 percent of Americans suffer from some form of periodontal disease, the major cause of adult tooth loss. In addition, cardiovascular disease, the leading killer of men and women in the United States, is a major public health issue contributing to 2,400 deaths each day. And while these two conditions are seemingly unrelated, research suggests that managing one disease may reduce the risk for the other.
› Verified 5 days ago
| Entity Name | Pensacola Hospitalist Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487254140 PECOS PAC ID: 5395159818 Enrollment ID: O20210125001604 |
News Archive
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute's long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group
Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Nearly 75 percent of Americans suffer from some form of periodontal disease, the major cause of adult tooth loss. In addition, cardiovascular disease, the leading killer of men and women in the United States, is a major public health issue contributing to 2,400 deaths each day. And while these two conditions are seemingly unrelated, research suggests that managing one disease may reduce the risk for the other.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey H Bordelon, MD Po Box 21850, Hot Springs, AR 71903-1850 Ph: (501) 609-2222 | Dr Jeffrey H Bordelon, MD 1 Mercy Ln, Suite 201, Hot Springs, AR 71913-6442 Ph: (501) 609-2222 |
News Archive
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute's long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group
Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Nearly 75 percent of Americans suffer from some form of periodontal disease, the major cause of adult tooth loss. In addition, cardiovascular disease, the leading killer of men and women in the United States, is a major public health issue contributing to 2,400 deaths each day. And while these two conditions are seemingly unrelated, research suggests that managing one disease may reduce the risk for the other.
› Verified 5 days ago
Jessica Treat, APRN Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Malvern Ave Ste 302, Hot Springs, AR 71901 Phone: 501-624-4700 Fax: 501-624-4705 | |
Pooja V Patel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 300 Werner St, Hot Springs, AR 71913 Phone: 501-622-1000 | |
Prabhakara K Reddy, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1455 Higdon Ferry Rd, Ste B, Hot Springs, AR 71913 Phone: 501-623-2731 Fax: 501-623-1660 | |
Dr. Timothy Eric Bowen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 Medical Park Pl, Hot Springs, AR 71901 Phone: 501-625-3400 Fax: 501-625-3402 | |
Oyidie Igbokidi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Heartcenter Ln, Hot Springs, AR 71913 Phone: 501-625-8400 Fax: 501-625-8446 | |
Dr. Gregory Allen St. John, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 130 Medical Park Pl, Hot Springs, AR 71901 Phone: 501-625-3400 Fax: 501-625-3402 | |
Cody Williams, APRN Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1455 Higdon Ferry Rd Ste B, Hot Springs, AR 71913 Phone: 501-623-2731 Fax: 501-623-1660 |